Virax Biolabs Group Limited (VRAX)
(Delayed Data from NSDQ)
$0.78 USD
-0.01 (-0.78%)
Updated Aug 8, 2025 03:40 PM ET
After-Market: $0.79 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Virax Biolabs Group Limited has a market cap of $3.43M, which represents its share price of $0.79 multiplied by its outstanding shares number of 4.34M. As a small-cap company, VRAX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VRAX 0.78 -0.01(-0.78%)
Will VRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRAX
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
VRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VRAX
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial ...
Virax Biolabs (VRAX) Faces Nasdaq Compliance Challenge | VRAX Stock News
Virax Biolabs receives noncompliance notice from Nasdaq
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price ...
Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule